Page 34 - Shimadzu Journal vol.9 Issue1
P. 34

Latest topics 4
                  Shimadzu Announces the Start of



                             Its Blood-Based Amyloid


                          Mass Spectrometry Service





            Shimadzu Scientific Instruments introduces the Amyloid Mass   The blood analysis works using a combination of immunoprecipita-
            Spectrometry (MS) Service for early screening of amyloid-positive   tion and MALDI-TOF mass spectrometry (IP-MS). This technique
            subjects. This simple blood analysis method enables early and ac-  was first established by a team of scientists including Shimadzu’s
            curate prediction of amyloid pathology in the brain with an easy-  Koichi Tanaka, who was awarded the Nobel Prize in Chemistry in
            to-acquire blood sample.                           2002 for developing a method for mass spectrometric analysis of
                                                               biological macromolecules.
            Although the screening analysis is Research Use Only and cannot
            diagnose Alzheimer’s disease, it is ideal for opening the door to
            new advancements in research, identifying suitable candidates for   Learn more about Shimadzu’s Amyloid
            clinical trials and helping pharmaceutical companies in their test-  MSTM Service:
            ing of candidate drugs.                             www.AmyloidMS.com

            Unlike conventional positron emission tomography (PET) imaging   For more scientific background about
                                                                 Shimadzu’s blood amyloid-beta analysis:
            and cerebrospinal fluid (CSF) testing methods, Shimadzu’s blood
                                                                 A. Nakamura, N. Kaneko et. al., “High performance plasma amyloid-β
            amyloid-beta analysis method is minimally invasive and suitable
                                                                 biomarkers for Alzheimer’s disease” doi: 10.1038/nature 25456
            for large-scale deployment. This new approach to blood analysis
            is capable of being used for predicting abnormal amyloid-beta   Amyloid MS is a trademark of Shimadzu Corporation.
                                                               For Research Use Only. Not for use in diagnostic procedures.
            concentration, which can be a marker for amyloid pathology in   Amyloid MS Service is for drug discovery and development only.
            the brain. New blood-based biomarkers were discovered in 2014
            by Shimadzu Corporation and the Japanese National Center for
            Geriatrics and Gerontology (NCGG).










                                                                                                Shimadzu Journal  vol.9  Issue1 33
   29   30   31   32   33   34   35   36